OR WAIT null SECS
Craigavon, N.I., November 1, 2017-Almac Group, the global contract development and manufacturing organization, announced the acquisition of 100% shares of BioClin Laboratories, an independent and privately owned organization based in Athlone, Ireland.
Established in 2002 and located in Garrycastle, just two hours away from Almac Group’s Headquarters in Northern Ireland, BioClin is internationally recognized for providing expert analytical services including cGMP pharmaceutical and biopharmaceutical analysis, GMP microbiology testing and GLP bioanalysis. The company also boasts Ireland’s leading GLP certified (INAB), cGMP certified (HPRA) and FDA registered contract laboratory.
BioClin’s bespoke 14,000sq ft modern facility significantly increases Almac’s analytical capacity and perfectly complements its existing business enabling strategic expansion and greater ability to serve clients’ needs globally. The acquisition will see BioClin’s analytical experts join Almac Sciences’ strong network of almost 600 employees across multiple sites in Europe and North America.
Almac also recently completed significant expansion of its existing analytical facilities at its global headquarter site in Northern Ireland with the creation of a new, bespoke, MHRA approved laboratory.
News of this acquisition comes just days after announcing a multi-million pound expansion of Almac owned, Arran Chemical Company, also based in Athlone, which substantially increased Almac’s manufacturing capacity for fine chemicals, pharmaceutical intermediates and advanced building blocks.
“We are delighted to announce this acquisition demonstrating further commitment to strategic growth and development of our global business.” stated Dr Stephen Barr, Managing Director, Almac Sciences. “Adding BioClin’s highly complementary analytical capacity and technical expertise to our existing capabilities, we are able to broaden our service offerings and address our global clients’ growing demands for a high quality, integrated, efficient service. We look forward to working with the BioClin team and plan to invest significantly in this facility.”
Mary Burke, Managing Director, BioClin Laboratories commented “We are very pleased to join Almac. With our shared values for outstanding quality, expertise, and innovation we see this as an excellent strategic fit for BioClin enabling us to expand and deliver an enhanced range of analytical solutions to an international client market."
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organiation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialization, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organization that has organically grown over almost 50 years and now employs close to 5,000 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).
About BioClin Laboratories
BioClin was established in 2002 and is internationally recognized for providing expert analytical services and rapid reporting of data to support drug development and product release. Its breadth of scientific experience and knowledge across a wide range of techniques, enables it to develop optimal methods that can be relied upon to run efficiently and meet regulatory requirements. BioClin joined Intertek Plc in February 2008 followed by a management buy-out on May 1, 2013.
BioClin is Irelands leading GLP certified (INAB), cGMP certified (HPRA) and FDA registered contract laboratory. BioClin maintains this position due to its versatility and capacity to integrate its exceptional technical expertise and quality management with a range of related services, enabling it to offer a complete range of development services to its clients.